Physician profile
Brad A Mouse
NPI 1588604979
$1,512.82
in general payments reported to CMS, 2019-2025
19 companies · $437 in 2025
The $437 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $164 · 2020: $290 · 2021: $159 · 2022: $77.49 · 2023: $247 · 2024: $139 · 2025: $437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $746 · Education: $76.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $746.47 |
| Education | $76.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $536.70 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $228.15 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $186.89 | 2019-2024 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $116.08 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.00 | 2020-2025 | Jardiance, Tradjenta |
| Astrazeneca Pharmaceuticals Lp | $61.75 | 2024-2025 | Airsupra |
| Glaxosmithkline, LLC. | $48.89 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.98 | 2023 | Xifaxan |
| Abbvie INC. | $41.24 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $34.11 | 2019-2025 | |
| Dermira, INC. | $22.84 | 2020 | |
| Abbott Laboratories | $20.26 | 2022 | |
| Allergan, INC. | $15.70 | 2020 | |
| Pfizer INC. | $14.53 | 2019 | |
| Philips North America LLC | $13.48 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $12.40 | 2021 | |
| Vbi Vaccine (Delaware) INC. | $12.28 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $11.33 | 2019 | |
| Clarus Therapeutics INC. | $11.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brad Mouse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.